Pancoast tumor classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 13: Line 13:
| style="background:#4479BA; color: #FFFFFF;" align="center" + |'''M'''
| style="background:#4479BA; color: #FFFFFF;" align="center" + |'''M'''
|-
|-
| style="background:#DCDCDC;" align="center" + |IA
| style="background:#DCDCDC;" align="center" + |IIB
| style="background:#F5F5F5;" + |T1
| style="background:#F5F5F5;" + |T3
| style="background:#F5F5F5;" + |N0
| style="background:#F5F5F5;" + |M0
|-
| style="background:#DCDCDC;" align="center" + |IB
| style="background:#F5F5F5;" + |T2
| style="background:#F5F5F5;" + |N0
| style="background:#F5F5F5;" + |N0
| style="background:#F5F5F5;" + |M0
| style="background:#F5F5F5;" + |M0
|-
|-
| style="background:#DCDCDC;" align="center" + |IIA
| style="background:#DCDCDC;" align="center" + |IIIA
| style="background:#F5F5F5;" + |T3
| style="background:#F5F5F5;" + |T3
| style="background:#F5F5F5;" + |N0
| style="background:#F5F5F5;" + |N1-2
| style="background:#F5F5F5;" + |M0
|-
| style="background:#DCDCDC;" align="center" + |IIB
| style="background:#F5F5F5;" + |T1-3
| style="background:#F5F5F5;" + |N1
| style="background:#F5F5F5;" + |M0
| style="background:#F5F5F5;" + |M0
|-
|-
| style="background:#DCDCDC;" align="center" + |III
| style="background:#DCDCDC;" align="center" + |IIIB
| style="background:#F5F5F5;" + |T4
| style="background:#F5F5F5;" + |T4
| style="background:#F5F5F5;" + |Any N
| style="background:#F5F5F5;" + |Any N
| style="background:#F5F5F5;" + |M0
| style="background:#F5F5F5;" + |M0
|-
|IIIB
|Any T
|N3
|M0
|-
|-
| style="background:#DCDCDC;" align="center" + |IV
| style="background:#DCDCDC;" align="center" + |IV
Line 44: Line 39:
|}
|}
{| class="wikitable" align="center"
{| class="wikitable" align="center"
| colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |'''AJCC 2010'''
| colspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" + |TNM-8th Edition
|-
|-
! rowspan="4" style="background:#DCDCDC;" align="center" + | T
! rowspan="4" style="background:#DCDCDC;" align="center" + | T
| style="background:#DCDCDC;" align="center" + | T1
| style="background:#DCDCDC;" align="center" + | T1
| style="background:#F5F5F5;" + |<2 cm in greatest dimension
| style="background:#F5F5F5;" + |Tumor size ≤3cm in greatest dimension
|-
|-
| style="background:#DCDCDC;" align="center" + |T2
| style="background:#DCDCDC;" align="center" + |T2
| style="background:#F5F5F5;" + |>2 cm in greatest dimension
| style="background:#F5F5F5;" + |
* Tumor size >3cm to ≤5cm
* Tumor of any size that
** invades the visceral pleura
** involves main bronchus, irrespective of distance to the carina
** shows an atelectasis or obstructive pneumonitis that extends to the hilum
|-
|-
| style="background:#DCDCDC;" align="center" + |T3
| style="background:#DCDCDC;" align="center" + |T3
| style="background:#F5F5F5;" + |Beyond the [[pancreas]] but without involvement of the [[superior mesenteric artery]]
| style="background:#F5F5F5;" + |
* Tumor size >5cm to 7cm
* Pancoast that involves thoracic nerve roots T1 and T2 only.
* Tumor of any size that
** invades the chest wall
** invades the pericardium
** invades the phrenic nerve
** involves main bronchus, irrespective of distance to the carina
** shows one or more satellite nodules in the same lung lobe
|-
|-
| style="background:#DCDCDC;" align="center" + |T4
| style="background:#DCDCDC;" align="center" + |T4
| style="background:#F5F5F5;" + |Involvement of the ''[[celiac axis]]'' or [[superior mesenteric artery]] (unresectable [[tumor]])
| style="background:#F5F5F5;" + |
* Tumor size >7cm
* Involvement of C8 or higher nerve roots, brachial plexus, subclavian vessels or spine
* Tumor of any size that
** invades mediastinal fat or mediastinal structures
** invades the diaphragm
** involves the carina
** shows one or more satellite nodules in another lobe on the ipsilateral side
|-
|-
! rowspan="2" style="background:#DCDCDC;" align="center" + | N
! rowspan="4" style="background:#DCDCDC;" align="center" + | N
| style="background:#DCDCDC;" align="center" + |N0
| style="background:#DCDCDC;" align="center" + |N0
| style="background:#F5F5F5;" + |No regional [[lymph node]] [[metastasis]]
| style="background:#F5F5F5;" + |No regional [[lymph node]] [[metastasis]]
|-
|-
| style="background:#DCDCDC;" align="center" + |N1
| style="background:#DCDCDC;" align="center" + |N1
| style="background:#F5F5F5;" + |Regional [[lymph node]] [[metastasis]]
| style="background:#F5F5F5;" + |Nodes are ipsilateral nodes within the lung up to hilar nodes.
|-
!N2
!Nodes represent ipsilateral mediastinal or subcarinal lymphadenopathy.
|-
!N3
!'''Nodes represent contralateral mediastinal or contralateral hilar lymphadenopathy or any scalene or supraclavicular nodes.'''
|-
|-
! rowspan="2" style="background:#DCDCDC;" align="center" + | M
! rowspan="2" style="background:#DCDCDC;" align="center" + | M

Revision as of 00:06, 20 February 2018


Pancoast tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pancoast tumor from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pancoast tumor classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pancoast tumor classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pancoast tumor classification

CDC onPancoast tumor classification

Pancoast tumor classification in the news

Blogs on Pancoast tumor classification

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Pancoast tumor classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Classification

  • The staging of pancoast tumor is based on the TNM system.
  • Pancoast tumors staging starts at T3  always, as there is invasion of chest wall. Invasion of vertebral body or the subclavian vessels is regarded as T4.
Stage T N M
IIB T3 N0 M0
IIIA T3 N1-2 M0
IIIB T4 Any N M0
IIIB Any T N3 M0
IV Any T Any N M1
TNM-8th Edition
T T1 Tumor size ≤3cm in greatest dimension
T2
  • Tumor size >3cm to ≤5cm
  • Tumor of any size that
    • invades the visceral pleura
    • involves main bronchus, irrespective of distance to the carina
    • shows an atelectasis or obstructive pneumonitis that extends to the hilum
T3
  • Tumor size >5cm to 7cm
  • Pancoast that involves thoracic nerve roots T1 and T2 only.
  • Tumor of any size that
    • invades the chest wall
    • invades the pericardium
    • invades the phrenic nerve
    • involves main bronchus, irrespective of distance to the carina
    • shows one or more satellite nodules in the same lung lobe
T4
  • Tumor size >7cm
  • Involvement of C8 or higher nerve roots, brachial plexus, subclavian vessels or spine
  • Tumor of any size that
    • invades mediastinal fat or mediastinal structures
    • invades the diaphragm
    • involves the carina
    • shows one or more satellite nodules in another lobe on the ipsilateral side
N N0 No regional lymph node metastasis
N1 Nodes are ipsilateral nodes within the lung up to hilar nodes.
N2 Nodes represent ipsilateral mediastinal or subcarinal lymphadenopathy.
N3 Nodes represent contralateral mediastinal or contralateral hilar lymphadenopathy or any scalene or supraclavicular nodes.
M M0 No distant metastasis
M1 Distant metastasis

There is no established system for the classification of [disease name].

OR

[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].

OR

[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].

OR

Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

The staging of [malignancy name] is based on the [staging system].

OR

There is no established system for the staging of [malignancy name].

Classification

  • There is no established system for the classification of [disease name].

OR

  • [Disease name] may be classified according to [classification method] into [number] subtypes/groups:
    • [Group1]
    • [Group2]
    • [Group3]
    • [Group4]

OR

  • [Disease name] may be classified into [large number > 6] subtypes based on:
    • [Classification method 1]
    • [Classification method 2]
    • [Classification method 3]
  • [Disease name] may be classified into several subtypes based on:
    • [Classification method 1]
    • [Classification method 2]
    • [Classification method 3]

OR

  • Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

  • If the staging system involves specific and characteristic findings and features:
  • According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

  • The staging of [malignancy name] is based on the [staging system].

OR

  • There is no established system for the staging of [malignancy name].

References

Template:WH Template:WS